ArticleMicroorganisms2025
Macrolide-Resistant
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Neutrophil-to-lymphocyte ratio mediates pulmonary consolidation through oxidative stress in children withAnnals of medicine · 2026Article
- Long-term National Trends in Pediatric Oral Antibiotic Prescriptions in Japan, 2011-2022.JMA journal · 2026Article
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Development of a Real-Time Polymerase Chain Reaction Assay to DetectDiagnostics (Basel, Switzerland) · 2026Article
- Timing of corticosteroid initiation and severe in-hospital outcomes in pediatric Mycoplasma pneumoniae pneumonia: a propensity score-matched cohort study.BMC pulmonary medicine · 2026Article
- The Post-Pandemic Return ofJournal of clinical medicine · 2026Article
- Molecular insights into macrolide resistant Mycoplasma pneumoniae isolates from outpatient clinics in Tehran, Iran.Scientific reports · 2026Article
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Post-pandemic resurgence and collapse ofFrontiers in public health · 2026Article
- Analysis of pathogenic characteristics of acute respiratory tract infections in children and the influence of environmental factors in Shijiazhuang area.Frontiers in cellular and infection microbiology · 2026Article
- A Case of Macrolide-Resistant Mycoplasma Pneumonia Developing Shortly After Macrolide-Susceptible Infection.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.